OpSens announces that its SavvyWire(TM) has been used in surgery
by CM Staff
The SavvyWire is a third-generation, intelligent, pre-shaped, structural guidewire with integrated pressure monitoring.
QUEBEC — OpSens Inc., a medical device cardiology-focused company delivering solutions based on its proprietary optical technology,announced that Dr. Josep Rodés-Cabau at the Quebec Heart and Lung Institute – Laval University, in Quebec City and Dr. Réda Ibrahim at The Montreal Heart Institute in Montreal, performed the first commercial cases with OpSens’ new SavvyWire(TM) guidewire in transcatheter aortic valve replacements, or TAVR procedures.
Dr. Rodés-Cabau commented, “SavvyWire optimizes the intervention, in line with the evolution of TAVR via the minimalist approach. The SavvyWire has unique properties that open the door to effective pacing, without the need for adjunctive devices or venous access. I am proud to collaborate with OpSens to bring this leading-edge technology to market.”
Dr Ibrahim said, “The SavvyWire allows me to have an efficient workflow while providing continuous and accurate hemodynamic measurements in an integrated manner in our cath lab. OpSens’ product supports our return to the accuracy of invasive pressure measurement while making the procedure safer and more efficient.”
Louis Laflamme, President and CEO of OpSens, said, “We are honored to see Drs. Rodés-Cabau and Ibrahim successfully use the SavvyWire for TAVR procedures in Canada. Their clinical work played a significant role in helping to advance the applications and market for TAVR. Structural heart procedures are rapidly growing worldwide, driven by the aging population and recent studies that demonstrate its benefit for a broader array of patients. As the TAVR procedure benefits a larger group of patients and with the minimalist approach growing in popularity within the medical community, the benefits of the SavvyWire could be significant.”
Following the marketing approval received from Health Canada ahead of schedule in April 2022, OpSens has begun a controlled release to a limited number of hospitals in Canada. U.S. Food and Drug Administration clearance is expected this fall, with full commercial launch in early 2023.
The SavvyWire is a third-generation, intelligent, pre-shaped, structural guidewire with integrated pressure monitoring, and it aims to improve procedural efficiency and clinical outcomes by allowing multiple steps over the same device without exchange. This device is designed to support the growing minimalist TAVR approach.